Pharmaceuticals, Biotechnology & Life Sciences

Merck KGaA’s Europe‑wide share distribution boosts liquidity and positions the company for value‑based reimbursement success, balancing cost, quality and patient access.

Pfizer’s new license with Novavax’s Matrix‑M adjuvant and sale of its ViiV stake signal a sharpened focus on high‑margin vaccine and biotech opportunities, boosting R&D speed and future profitability.

Johnson & Johnson’s Q4 2025 earnings and Caplyta’s Phase 3 data hint at a potential boost to its pharmaceutical segment, with promising antidepressant results and a solid 18 % annual return.

EMA approves Enhertu as first‑line HER2‑positive breast cancer therapy, boosting Daiichi Sankyo’s oncology market, pricing strategy, and future M&A prospects.

Qiagen NV Q4 2025 results: 6 % revenue rise, 18 % EBITDA, €250 M cash, short‑interest drop and a strategic roadmap for diagnostics, research instruments and biotech partnerships – a resilient growth play amid EU market‑access pressures.

Roche Holding AG’s AI‑driven R&D, diversified pipeline and emerging market growth face patent cliffs, regulatory shifts and investor uncertainty – a nuanced analysis for informed investors.

Explore Astellas Pharma’s analyst outlook, partnership strategy, and clinical pipeline to understand its growth potential and impact on patient access.

Thermo Fisher Scientific’s robust $12.3 B revenue surge, strong cash flow, and AI‑driven diagnostic strategy position it for long‑term growth amid evolving genomic data‑privacy rules.

Discover how Bayer AG’s stock surge is driven by a potential glyphosate ruling, patent cliffs, and strategic moves in pharma, biotech, and diagnostics.

New Novo Nordisk earnings outlook shows modest EPS lift, but CEO warns of patent expiry and rising competition. Oral Wegovy’s launch could boost growth while regulatory hurdles loom.